WO2023027670A3 - Lyophilized levosimendan compositions - Google Patents

Lyophilized levosimendan compositions Download PDF

Info

Publication number
WO2023027670A3
WO2023027670A3 PCT/TR2022/050883 TR2022050883W WO2023027670A3 WO 2023027670 A3 WO2023027670 A3 WO 2023027670A3 TR 2022050883 W TR2022050883 W TR 2022050883W WO 2023027670 A3 WO2023027670 A3 WO 2023027670A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
levosimendan
lyophilized
kollidon
tri
Prior art date
Application number
PCT/TR2022/050883
Other languages
French (fr)
Other versions
WO2023027670A2 (en
Inventor
Samiye FICICIOGLU
Celil ULUTURK
Original Assignee
Tum Ekip Ilac Anonim Sirketi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from TR2021/013305 external-priority patent/TR2021013305A2/en
Application filed by Tum Ekip Ilac Anonim Sirketi filed Critical Tum Ekip Ilac Anonim Sirketi
Publication of WO2023027670A2 publication Critical patent/WO2023027670A2/en
Publication of WO2023027670A3 publication Critical patent/WO2023027670A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

The invention relates to the pharmaceutical compositions in the form of the lyophilized powder, which do not contain alcohol, comprising Levosimendan as an active ingredient or a pharmaceutically acceptable salt thereof, Kollidon PF-17 as a solubilizing agent and tri-sodium citrate as a buffering agent, preparation and use of these compositions.
PCT/TR2022/050883 2021-08-23 2022-08-20 Lyophilized levosimendan compositions WO2023027670A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR2021013305 2021-08-23
TR2021/013305 TR2021013305A2 (en) 2021-08-23 LYOPHILIZED LEVOSIMENDAN FORMULATIONS

Publications (2)

Publication Number Publication Date
WO2023027670A2 WO2023027670A2 (en) 2023-03-02
WO2023027670A3 true WO2023027670A3 (en) 2023-05-11

Family

ID=85323520

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/TR2022/050883 WO2023027670A2 (en) 2021-08-23 2022-08-20 Lyophilized levosimendan compositions

Country Status (1)

Country Link
WO (1) WO2023027670A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116473930B (en) * 2023-05-17 2023-12-15 山东泰合医药科技有限公司 Levosimendan for injection and preparation method thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6346273B1 (en) * 1997-07-23 2002-02-12 Farmigea S.P.A. Process for solubilizing pharmaceutically active ingredients in water and in aqueous vehicles
EP1210085A2 (en) * 1999-09-10 2002-06-05 Orion Corporation Pharmaceutical solutions of levosimendan
WO2018085476A1 (en) * 2016-11-02 2018-05-11 Centrexion Therapeutics Corporation Stable aqueous capsaicin injectable formulations and medical uses thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6346273B1 (en) * 1997-07-23 2002-02-12 Farmigea S.P.A. Process for solubilizing pharmaceutically active ingredients in water and in aqueous vehicles
EP1210085A2 (en) * 1999-09-10 2002-06-05 Orion Corporation Pharmaceutical solutions of levosimendan
WO2018085476A1 (en) * 2016-11-02 2018-05-11 Centrexion Therapeutics Corporation Stable aqueous capsaicin injectable formulations and medical uses thereof

Also Published As

Publication number Publication date
WO2023027670A2 (en) 2023-03-02

Similar Documents

Publication Publication Date Title
WO2019036008A8 (en) Lipids for use in lipid nanoparticle formulations
WO2004066910A3 (en) Controlled release modifying complex and pharmaceutical compositions thereof
WO2018165404A8 (en) Pharmaceutical formulations of phloroglucinol and trimethylphloroglucinol
HUP0302319A2 (en) Pharmaceutical compositions for the oral delivery of pharmacologically active agents
CA3030422C (en) Stabilizing excipients for therapeutic protein formulations
RS50937B (en) Pharmaceutical compositions comprising metformine and glibenclamide for the treatment of type-ii diabetes mellitus
HUP0000587A1 (en) Pharmaceutical composition containing tacrolimus (fk506)
WO2023027670A3 (en) Lyophilized levosimendan compositions
WO2006053089A3 (en) Methods and formulations for making pharmaceutical compositions containing bupropion
WO2020138791A3 (en) Sustained-release preparation comprising tofacitinib or pharmaceutically acceptable salt thereof and manufacturing method therefor
WO2007011989A3 (en) Multiple active pharmaceutical ingredients combined in discrete inhalation particles and formulations thereof
WO2020176801A9 (en) Amniotic fluid-derived extracellular vesicles and uses thereof for wound healing
WO2019203771A3 (en) Solid oral pharmaceutical compositions comprising sitagliptin
WO2012085284A3 (en) High drug load pharmaceutical formulations comprising dronedarone and its pharmaceutically acceptable salts
MX2021010144A (en) Pharmaceutical formulations.
WO2005115346A3 (en) Pharmaceutical composition containing risperidone
WO2020013777A3 (en) Tablet formulations comprising metformin and sitagliptin
MX2017004476A (en) Composition comprising at least one dry powder obtained by spray drying to increase the stability of the formulation.
MX2022006940A (en) Pharmaceutical compositions comprising cabotegravir.
HRP20201436T1 (en) Macrogols for application to the mucosa, and therapeutic uses thereof
CA2567400A1 (en) Solid pharmaceutical formulation
WO2023114943A3 (en) Lipids for use in lipid nanoparticle formulations
WO2007037790A3 (en) Modified release famciclovir compositions
WO2018069805A3 (en) Method for preparation of liquid oral composition of l-thyroxin
ES2266502T3 (en) SYNTHETIC FILLING COMPOSITION.

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE